About Us
Executive Management
Board of Directors
Corporate Governance
Contact Us
Pipeline
Btk Inhibitor PCI-32765
and Inhibitor Series for Autoimmune Diseases
Factor VIIa Inhibitor
PCI-27483
Histone Deacetylase Inhibitor Program
Motexafin Gadolinium
Glossary of Terms
Clinical Trials
PCYC 04753 Btk Inhibitor
B-cell Lymphoma
PCYC 1102 CA Btk Inhibitor
CLL/SLL
PCYC 1103 CA Btk Inhibitor
B-cell Lymphoma and CLL
PCYC 1104 CA Btk Inhibitor
Relapsed or Refractory Mantle cell Lymphoma
PCYC 1106 CA Btk Inhibitor
Relapsed or Refractory Non-Hodgkin's DLBCL Lymphoma
PCYC 1108 CA Btk Inhibitor
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PCYC 1109 CA Btk Inhibitor
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia
PCYC 1001 Factor VIIa Inhibitor Pancreatic Cancer
PCYC 0403 HDAC Inhibitor
B-cell Lymphoma
RTOG 0513 MGd
Glioblastoma
Glossary of Terms
Investors & Media
Stock Information
Events & Webcasts
SEC Filings
Corporate Governance
Press Releases
Annual Reports & Meetings
Presentations & Articles
Request Printed Materials
Investor FAQs
Glossary of Terms
IR Contact
Careers
Contact Us
Contact Info & Map
IR Contact
Home
Investor Relations
Print
Email
Stock Information
Events & Webcasts
SEC Filings
Corporate Governance
Press Releases
Annual Reports & Meetings
Presentations & Articles
Information Request
Investor FAQs
Glossary of Terms
Contact IR
SHAREHOLDER TOOLS
Details on this event are not available.
Back to previous page
